|
See related Plavix film-coated tab information |
|
|
|
Manufacturer |
Bristol-Myers Squibb/sanofi-aventis |
|
Distributor |
Hong Kong: LF Asia/Macau: The Glory Medicina |
|
Contents |
Clopidogrel bisulfate |
|
Indications |
Prevention of atherothrombotic events in MI (from a few days until <35 days), ischaemic stroke (from 7 days until <6 mth), or established peripheral arterial disease; in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q wave MI), including patients undergoing stent placement following percutaneous coronary intervention in combination w/ aspirin; in ST segment elevation acute MI in combination w/ aspirin in patients eligible for thrombolytic therapy.
Click to view Plavix detailed prescribing infomation |
|
Dosage |
75 mg once daily. Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q wave MI), including patients undergoing stent placement following percutaneous coronary intervention Loading dose: 300 mg as a single dose. Maintenance: 75 mg once daily w/ aspirin 75-325 mg daily (optimal aspirin dose: 100 mg daily). ST segment elevation acute MI 75 mg once daily w/ loading dose w/ aspirin w/ or w/o thrombolytics. Elderly >75 yr Initiate w/o loading dose.
Click to view Plavix detailed prescribing infomation |
|
Overdosage |
View Plavix overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Severe liver impairment. Peptic ulcer & intracranial haemorrhage. Lactation.
Click to view Plavix detailed prescribing infomation |
|
Special Precautions |
Patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions. Patients w/ moderate hepatic disease who may have bleeding diatheses. Renal impairment. Patients w/ genetically reduced CYP2C19 function. Pregnancy. Childn <18 yr.
Click to view Plavix detailed prescribing infomation |
|
Adverse Drug Reactions |
GI bleeding, purpura, bruising, haematoma, epistaxis, haematuria, ocular haemorrhage, intracranial bleeding, abdominal pain, dyspepsia, gastritis & constipation, rash, pruritus, diarrhoea.
View ADR Monitoring Form |
|
Drug Interactions |
Oral anticoagulants, glycoprotein IIb/IIIa inhibitors, aspirin, heparin, thrombolytics or NSAIDs including COX-2 inhibitors, CYP2C19 inhibitors, proton-pump inhibitors.
View more drug interactions with Plavix |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Plavix storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Plavix description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Plavix mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
